RU2661764C2 - Композиции и способы на основе dac hyp - Google Patents

Композиции и способы на основе dac hyp Download PDF

Info

Publication number
RU2661764C2
RU2661764C2 RU2012121876A RU2012121876A RU2661764C2 RU 2661764 C2 RU2661764 C2 RU 2661764C2 RU 2012121876 A RU2012121876 A RU 2012121876A RU 2012121876 A RU2012121876 A RU 2012121876A RU 2661764 C2 RU2661764 C2 RU 2661764C2
Authority
RU
Russia
Prior art keywords
dac
daclizumab
dac hyp
cells
buffer
Prior art date
Application number
RU2012121876A
Other languages
English (en)
Russian (ru)
Other versions
RU2012121876A (ru
Inventor
Теймар ХАРТМАН
Пол У. СОЭР
Джон Е. БЕРКИ
Марк С. ВЕССОН
Пин И. Хуан
Томас Дж. РОБИНСОН
Бреден ПАРТРИДЖ
Дж. Юнь Тсо
Original Assignee
Эббви Байотекнолоджи Лтд.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эббви Байотекнолоджи Лтд., filed Critical Эббви Байотекнолоджи Лтд.,
Publication of RU2012121876A publication Critical patent/RU2012121876A/ru
Application granted granted Critical
Publication of RU2661764C2 publication Critical patent/RU2661764C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/95—Protein-free medium and culture conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
RU2012121876A 2011-05-27 2012-05-25 Композиции и способы на основе dac hyp RU2661764C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161490998P 2011-05-27 2011-05-27
US61/490,998 2011-05-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2018119112A Division RU2018119112A (ru) 2011-05-27 2012-05-25 Композиции и способы на основе dac hyp

Publications (2)

Publication Number Publication Date
RU2012121876A RU2012121876A (ru) 2013-11-27
RU2661764C2 true RU2661764C2 (ru) 2018-07-19

Family

ID=46177353

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2012121876A RU2661764C2 (ru) 2011-05-27 2012-05-25 Композиции и способы на основе dac hyp
RU2018119112A RU2018119112A (ru) 2011-05-27 2012-05-25 Композиции и способы на основе dac hyp

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2018119112A RU2018119112A (ru) 2011-05-27 2012-05-25 Композиции и способы на основе dac hyp

Country Status (10)

Country Link
US (7) US20120301429A1 (enExample)
EP (1) EP2527429A3 (enExample)
JP (4) JP6055615B2 (enExample)
CN (2) CN107090040A (enExample)
AU (4) AU2012203095B2 (enExample)
BR (1) BR102012012673A8 (enExample)
CA (1) CA2777978A1 (enExample)
MX (1) MX339533B (enExample)
RU (2) RU2661764C2 (enExample)
SG (1) SG185920A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2661764C2 (ru) * 2011-05-27 2018-07-19 Эббви Байотекнолоджи Лтд., Композиции и способы на основе dac hyp
EP2741773A1 (en) * 2011-08-08 2014-06-18 AbbVie Biotherapeutics Inc. Methods of treating progressive forms of multiple sclerosis
CA2857298A1 (en) * 2011-11-30 2013-06-06 Abbvie Biotherapeutics Inc. Vectors and host cells comprising a modified sv40 promoter for protein expression
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
SG11201510788XA (en) 2013-09-04 2016-01-28 Emd Millipore Corp Protein a chromatography
GB201503578D0 (en) * 2015-03-03 2015-04-15 Ge Healthcare Bio Sciences Ab Sanitization method for affinity chromatography matrices
ES2936088T3 (es) * 2015-03-23 2023-03-14 Alexion Pharma Inc Filtración de virus
CA2938333A1 (en) 2015-08-12 2017-02-12 Pfizer Inc. Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
ES2823173T3 (es) 2016-01-27 2021-05-06 Just Biotherapeutics Inc Promotor híbrido y usos del mismo
WO2018027195A1 (en) 2016-08-05 2018-02-08 Abbvie Biotherapeutics Inc. Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same
CA3233933A1 (en) * 2017-01-30 2018-08-02 Regeneron Pharmaceuticals, Inc. Compositions and methods for reducing bioburden in chromatography
AU2018392697B2 (en) * 2017-12-21 2025-08-14 Genzyme Corporation Methods for enhanced removal of impurities during protein a chromatography
EP3956046A1 (en) * 2019-04-17 2022-02-23 Bristol-Myers Squibb Company Methods for regenerating chromatography resins
KR102731889B1 (ko) * 2019-07-18 2024-11-19 에이비온 주식회사 2당화된 인터페론-베타 단백질의 정제 방법
US12649764B2 (en) * 2019-08-01 2026-06-09 Regeneron Pharmaceuticals, Inc. Method for viral inactivation
IL309560B2 (en) 2019-12-06 2025-05-01 Regeneron Pharma Anti-VEGF protein preparations and methods for their production
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
JP7631742B2 (ja) * 2020-11-10 2025-02-19 東ソー株式会社 ペプチド性リガンド固定化カラムの洗浄方法
MX2023012903A (es) * 2021-05-03 2023-11-08 Boehringer Ingelheim Int Metodo para producir spesolimab.
CN114181300A (zh) * 2021-12-20 2022-03-15 方坦思(上海)生物医药有限公司 一种高纯度单克隆抗体的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2003130636A (ru) * 2001-04-06 2005-04-10 Юниверсити Оф Бристоль (Gb) Применение cd25-связывающих молекул для лечения пациентов, устойчивых к стероидам
US20050276799A1 (en) * 2002-10-15 2005-12-15 Hinton Paul R Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1614693A1 (en) * 2003-03-31 2006-01-11 Kirin Beer Kabushiki Kaisha Purification of human monoclonal antibody and human polyclonal antibody

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1430566A (en) * 1974-11-15 1976-03-31 Nestel Sa Isolation of proteins
US7442777B2 (en) * 2000-11-29 2008-10-28 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
JP2005325133A (ja) * 2001-10-15 2005-11-24 Kirin Brewery Co Ltd 抗ｈｌａ−ｄｒ抗体の利用
US20040002135A1 (en) * 2002-03-28 2004-01-01 Sauer Paul W. Adapted NS0 cell lines with the ability to grow under glutamine-free conditions
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
CA2655246A1 (en) 2006-06-09 2007-12-21 University Of Maryland, Baltimore Glycosylation engineered antibody therapy
EP2069387A4 (en) * 2006-06-14 2011-02-02 Glaxosmithkline Llc METHODS OF PURIFYING ANTIBODIES USING HYDROXYAPATITE CERAMIC
WO2008004931A1 (en) * 2006-07-06 2008-01-10 Ge Healthcare Bio-Sciences Ab Disinfection/sanitation method where the material is treated with a solution comprising benzyl alcohol and c2-3 alcohol
CA2717614A1 (en) * 2008-03-11 2009-09-17 Genentech, Inc. Antibodies with enhanced adcc function
BRPI0918842A2 (pt) * 2008-08-28 2015-12-08 Abbott Biotherapeutics Corp método para tratar pacientes com esclerose múltipla com anticorpos anti-il2r
US20120329709A1 (en) * 2009-05-26 2012-12-27 Brian Edward Collins Production of glycoproteins
WO2010141855A1 (en) 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
US8536316B2 (en) * 2009-08-07 2013-09-17 Emd Millipore Corporation Methods for purifying a target protein from one or more impurities in a sample
US20110053223A1 (en) 2009-08-14 2011-03-03 Robert Bayer Cell culture methods to make antibodies with enhanced adcc function
US10087236B2 (en) * 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US8993524B2 (en) 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
RU2661764C2 (ru) * 2011-05-27 2018-07-19 Эббви Байотекнолоджи Лтд., Композиции и способы на основе dac hyp

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2003130636A (ru) * 2001-04-06 2005-04-10 Юниверсити Оф Бристоль (Gb) Применение cd25-связывающих молекул для лечения пациентов, устойчивых к стероидам
US20050276799A1 (en) * 2002-10-15 2005-12-15 Hinton Paul R Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1614693A1 (en) * 2003-03-31 2006-01-11 Kirin Beer Kabushiki Kaisha Purification of human monoclonal antibody and human polyclonal antibody

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BURKY J. et al., Protein-free fed-batch culture of non-GS NS0 cell lines for production of recombinant antibodies, BIOTECH & BIOENG, 2007, v. 96, p. 281-293. *
COLE M.S. et al., Human lgG2 variants of chimeric anti-CD2 are nonmitogenic to T-cell, J. IMMUN. AAI, 1997, v. 159, p. 3613-3621. *
HARTMAN T. et al., Derivation and characterization of cholesterol-independent non-GS NS0 cell lines for production of recombinant antibodies, BIOTECH & BIOENG, 2007, v. 96, p. 294-306. *
KOSTELNY S.A. et al., Humanization and characterization of the anti-HLA-DR antibody 1D10, INT. J. CANC. UICC, 2001, v. 93, p. 557-560. *
LYDERSEN B.K. et al., Acid precipitation of mammalian cell fermentation broth, ANN.N.Y. AC. SCI., 1994, v. 745, p. 222-231. *
SATOH M. et al., Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies, EXP. OP. BIO. THER., 2006, v. 6, p. 1161-1173. *
ZHAO L. et al., Methabolic characteristics of GS-NS0 myeloma cells producing anti-CD25 monoclonal antibody in serum-free culture, CH. J. BIOTECH., 2009, v. 25, p. 1069-1076. *
ZHAO L. et al., Methabolic characteristics of GS-NS0 myeloma cells producing anti-CD25 monoclonal antibody in serum-free culture, CH. J. BIOTECH., 2009, v. 25, p. 1069-1076. SATOH M. et al., Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies, EXP. OP. BIO. THER., 2006, v. 6, p. 1161-1173. BURKY J. et al., Protein-free fed-batch culture of non-GS NS0 cell lines for production of recombinant antibodies, BIOTECH & BIOENG, 2007, v. 96, p. 281-293. HARTMAN T. et al., Derivation and characterization of cholesterol-independent non-GS NS0 cell lines for production of recombinant antibodies, BIOTECH & BIOENG, 2007, v. 96, p. 294-306. COLE M.S. et al., Human lgG2 variants of chimeric anti-CD2 are nonmitogenic to T-cell, J. IMMUN. AAI, 1997, v. 159, p. 3613-3621. KOSTELNY S.A. et al., Humanization and characterization of the anti-HLA-DR antibody 1D10, INT. J. CANC. UICC, 2001, v. 93, p. 557-560. *

Also Published As

Publication number Publication date
RU2012121876A (ru) 2013-11-27
US9260528B2 (en) 2016-02-16
BR102012012673A8 (pt) 2021-02-17
JP2012244993A (ja) 2012-12-13
AU2018200654A1 (en) 2018-02-15
US20200157230A1 (en) 2020-05-21
AU2016202873A1 (en) 2016-05-26
JP2016210796A (ja) 2016-12-15
CN102796705A (zh) 2012-11-28
JP2018134091A (ja) 2018-08-30
EP2527429A3 (en) 2013-10-30
CN107090040A (zh) 2017-08-25
US20120301429A1 (en) 2012-11-29
US20180127506A1 (en) 2018-05-10
AU2012203095B2 (en) 2016-02-04
JP6055615B2 (ja) 2016-12-27
RU2018119112A (ru) 2018-11-07
MX2012006115A (es) 2012-12-04
SG185920A1 (en) 2012-12-28
CA2777978A1 (en) 2012-11-27
US20150197573A1 (en) 2015-07-16
US9815903B2 (en) 2017-11-14
EP2527429A2 (en) 2012-11-28
AU2012203095A1 (en) 2012-12-13
AU2016202873B2 (en) 2018-02-22
US20150274832A1 (en) 2015-10-01
BR102012012673A2 (pt) 2015-11-17
US9676860B2 (en) 2017-06-13
JP2020078348A (ja) 2020-05-28
US20170247461A1 (en) 2017-08-31
US9340619B2 (en) 2016-05-17
AU2020202298A1 (en) 2020-04-23
US20150203583A1 (en) 2015-07-23
MX339533B (es) 2016-05-30

Similar Documents

Publication Publication Date Title
US9815903B2 (en) DAC HYP compositions
EP4008728B1 (en) Cd70 binding molecules and methods of use thereof
US20180127507A1 (en) Methods of treating progressive forms of multiple sclerosis
JP2015502340A (ja) ｉＮＫＴに対するヒト化抗体
TW201942135A (zh) 抗cd27 抗體、其抗原結合片段及其醫藥用途
JP2018516537A (ja) アゴニスト性の活性を有する抗原結合複合体及びその使用方法
WO2023235764A1 (en) Anti-cd20 antibody compositions
HK1178205A (en) Dac hyp compositions and methods
EP4626917A1 (en) Antibodies against apoptosis-associated speck-like protein containing a card (asc) and uses thereof
HK40074543A (en) Cd70 binding molecules and methods of use thereof
CN120712102A (zh) 对baff-r和cd19具特异性的嵌合抗原受体及其方法和用途
HK40019175B (en) Cd70 binding molecules and methods of use thereof

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant